Results 51 to 60 of about 12,655 (217)

Eculizumab experience in an adult patient with atypical hemolytic uremic syndrome

Saudi Journal of Kidney Diseases and Transplantation, 2017
Atypical hemolytic-uremic syndrome is a disease characterized by nonimmune hemolytic anemia, thrombocytopenia, and renal failure. In this study, we present a case of a patient with atypical hemolytic-uremic syndrome treated successfully with eculizumab ...
Funda Sari, Ayça Inci, Volkan Karakus, Banu Yilmaz, Metin Sarikaya, Refik Olmaz, Erdal Kurtoglu   +6 more
doaj   +1 more source

Factor H gene variants in Japanese: Its relation to atypical hemolytic uremic syndrome [PDF]

, 2011
Mutations and polymorphisms of factor H gene (FH1) are known to be closely involved in the developmentof atypical hemolytic uremic syndrome (aHUS). Several groups have identified disease risk mutations andpolymorphisms of FH1 for the development of aHUS,
Fujihara Noriko, Hidaka Yoshihiko, Hirota-Kawadobora Masako, Honda Takayuki, Koike Kenichi, Kubota Seiko, Matsuda Kazuyuki, Mukai Saki, Takezawa Yuka, Yamauchi Kazuyoshi, 山内 一由   +10 more
core   +1 more source

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first‐in‐class, highly potent specific inhibitor of factor B, a key AP protease. Experimental Approach The analysis included data from two phase 1 randomised, volunteer‐blinded, placebo‐controlled studies: Study 1, a single ...
Irina Baltcheva, Guido Junge, Kenneth Kulmatycki, Robert Schmouder, Anna Schubart, Marie‐Anne Valentin   +5 more
wiley   +1 more source

Reversible cerebral vasoconstriction syndrome: A narrative review

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This review summarizes current insights into Reversible cerebral vasoconstriction syndrome (RCVS) diagnosis, management, and outcomes. RCVS is a cerebrovascular disorder characterized by recurrent thunderclap headaches and transient segmental vasoconstriction of cerebral arteries, typically resolving within 3 months ...
Ícaro Araújo de Sousa, Abner da Silva Machado, Arthur de Oliveira Veras, Thiago Oscar Goulart, Sarah Galassi Tatsuta, Trajano Aguiar Pires Gonçalves, Eva Rocha, Octávio Marques Pontes‐Neto   +7 more
wiley   +1 more source

When the environment and mutations affect organ systems [PDF]

, 2017
Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy (TMA) with a genetic predisposition. Like other TMAs, it presents clinically with thrombocytopenia and microangiopathic hemolytic anemia, which is accompanied by disruption of
Abu Ghanimeh, Mouhanna, Abughanimeh, Omar, Qasem, Abdulraheem, Qasrawi, Ayman   +3 more
core   +1 more source

Common Hematologic Emergencies—Acute Promyelocytic Leukemia and Microangiopathic Hemolytic Anemias—A Pivotal Role of Clinical Laboratory

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova, Nicolas Ulrich Edgar, Anton V. Rets   +2 more
wiley   +1 more source

Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome [PDF]

, 2007
The atypical form of the kidney disease hemolytic uremic syndrome (aHUS) is associated with defective complement regulation. In addition to mutations in complement regulators, factor H (FH)-specific autoantibodies have been reported for aHUS patients ...
Dahse, H. M., Hoyer, P. F., Józsi, Mihály, Liu, W. S., Strobel, S.   +4 more
core   +1 more source

Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors

Transplant Infectious Disease, EarlyView.
In this retrospective single‐center study of 220 kidney transplants from SARS‐CoV‐2 NAT+, NAT+ with COVID as cause of death (CoV‐COD) and NATneg donors, we found no significant difference in rejection or kidney pathologies at 1 year, and death, graft loss, or eGFR at 3 years by CoV‐donor status.
Christine E. Koval, Mohamed Eltemamy, Nabin K. Shrestha, Leal Herlitz, Emilio D. Poggio, Alvin C. Wee   +5 more
wiley   +1 more source

Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: a case report

BMC Nephrology, 2019
Background Atypical hemolytic uremic syndrome (aHUS) is a disorder of the microvasculature with hemolytic anemia, thrombocytopenia and acute kidney injury.
Subagini Nagarajah, Martin Tepel, Christian Nielsen, Kristian Assing, Yaseelan Palarasah, Lise Lotte Torvin Andersen, Lotte Borg Lange, Claus Bistrup   +7 more
doaj   +1 more source

Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

Romanian Journal of Internal Medicine, 2022
Introduction. The aim was to evaluate the effect of therapeutic plasma exchange (TPE) and eculizumab on hematological and renal survival in atypical hemolytic uremic syndrome (aHUS), and additionally, to examine the reliability of discontinuation of ...
Yeter Hasan H., Derici Ulver, Arinsoy Turgay, Altok Kadriye, Erten Yasemin, Guz Galip   +5 more
doaj   +1 more source